Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:BFRINASDAQ:CYCNNASDAQ:EVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.81-7.1%$7.66$6.51▼$13.27$8.27M1.6293,866 shs1,153 shsBFRIBiofrontera$0.61-0.6%$0.75$0.58▼$2.22$5.76M0.37922,965 shs41,996 shsCYCNCyclerion Therapeutics$2.85+3.6%$2.90$1.27▼$9.47$9.15M1.671.29 million shs18,263 shsEVAXEvaxion Biotech A/S$2.30-12.5%$1.60$1.20▼$19.95$3.23M-0.24608,922 shs168,173 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-6.61%-2.80%+6.30%-5.95%-6.39%BFRIBiofrontera-3.96%-5.01%-24.23%-37.10%-41.55%CYCNCyclerion Therapeutics-5.82%-10.42%-25.68%-2.48%-0.36%EVAXEvaxion Biotech A/S+11.44%+52.02%+59.39%+25.24%-86.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.7392 of 5 stars3.55.00.00.03.30.80.0BFRIBiofrontera2.1433 of 5 stars3.53.00.00.01.40.01.3CYCNCyclerion Therapeutics2.5451 of 5 stars0.05.00.00.03.63.30.6EVAXEvaxion Biotech A/S2.7342 of 5 stars3.55.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00284.32% UpsideBFRIBiofrontera 3.00Buy$2.75350.67% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/AEVAXEvaxion Biotech A/S 3.00Buy$10.00334.78% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, CYCN, BFRI, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.754/2/2025EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K20.48N/AN/A$1.20 per share6.51BFRIBiofrontera$38.00M0.15N/AN/A$3.16 per share0.19CYCNCyclerion Therapeutics$2.08M4.40N/AN/A$4.62 per share0.62EVAXEvaxion Biotech A/S$3.34M0.96N/AN/A($5.83) per share-0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%6/2/2025 (Estimated)BFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)EVAXEvaxion Biotech A/S-$22.12M-$0.72N/AN/AN/A-347.83%N/A-79.40%8/12/2025 (Estimated)Latest EVAX, CYCN, BFRI, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025ADXNAddex Therapeutics-$1.4197N/AN/AN/AN/AN/A5/27/2025Q1 2025EVAXEvaxion Biotech A/S-$0.65-$0.29+$0.36-$0.29$0.06 millionN/A5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million4/1/2025Q4 2024EVAXEvaxion Biotech A/S-$0.26-$0.07+$0.19-$0.07$1.66 million$0.12 million3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59BFRIBiofronteraN/A1.530.94CYCNCyclerion TherapeuticsN/A5.075.07EVAXEvaxion Biotech A/S7.991.002.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%BFRIBiofrontera10.08%CYCNCyclerion Therapeutics75.62%EVAXEvaxion Biotech A/S11.04%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%BFRIBiofrontera1.20%CYCNCyclerion Therapeutics34.30%EVAXEvaxion Biotech A/S41.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableBFRIBiofrontera709.45 million7.73 millionNo DataCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataEVAXEvaxion Biotech A/S601.40 million685,000No DataEVAX, CYCN, BFRI, and ADXN HeadlinesRecent News About These CompaniesEvaxion Biotech Reports Q1 2025 Progress and FinancialsMay 28 at 12:42 AM | tipranks.comEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptMay 27 at 11:06 AM | seekingalpha.comEvaxion Biotech: Evaxion announces business update and first quarter 2025 financial resultsMay 27 at 10:46 AM | finanznachrichten.deEvaxion announces business update and first quarter 2025 financial resultsMay 27 at 7:30 AM | globenewswire.comA Look at Evaxion Biotech's Upcoming Earnings ReportMay 26 at 11:13 AM | benzinga.comEvaxion Biotech: Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025May 25, 2025 | finanznachrichten.deEvaxion A/S to Host Conference Call for Q1 2025 Financial Results and Business Update on May 27, 2025May 25, 2025 | nasdaq.comEvaxion at Sidoti Conference: AI-Driven Drug Development StrategyMay 23, 2025 | investing.comEvaxion to announce business update and first quarter 2025 financial results on May 27, 2025May 23, 2025 | globenewswire.comEvaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01May 22, 2025 | globenewswire.comEvaxion A/S ADRMay 21, 2025 | wsj.comEvaxion Biotech A/S (EVAX) to Release Quarterly Earnings on TuesdayMay 20, 2025 | americanbankingnews.comEvaxion Biotech A/S Announces Key Resolutions from April 2025 AGMMay 5, 2025 | tipranks.comEvaxion Reports Positive Data For Vaccine Candidate EVX-01April 30, 2025 | nasdaq.comEvaxion Biotech Reports 80% Tumor-Specific Immune Response from EVX-01 Cancer Vaccine in Phase 2 TrialApril 30, 2025 | nasdaq.com80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meetingApril 28, 2025 | globenewswire.comEvaxion Biotech: Evaxion to present at World Vaccine CongressApril 10, 2025 | finanznachrichten.deEvaxion to present at World Vaccine CongressApril 10, 2025 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call TranscriptApril 4, 2025 | msn.comEarnings call transcript: Evaxion Biotech Q4 2024 sees improved financialsApril 3, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, CYCN, BFRI, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$7.80 -0.60 (-7.08%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Biofrontera NASDAQ:BFRI$0.61 0.00 (-0.57%) Closing price 04:00 PM EasternExtended Trading$0.59 -0.02 (-3.97%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cyclerion Therapeutics NASDAQ:CYCN$2.85 +0.10 (+3.64%) Closing price 03:58 PM EasternExtended Trading$2.95 +0.10 (+3.51%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Evaxion Biotech A/S NASDAQ:EVAX$2.30 -0.33 (-12.55%) Closing price 04:00 PM EasternExtended Trading$2.35 +0.05 (+1.96%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
